Kenacort-T (Triamcinolone Acetonide)

Kenacort‑T, a glucocorticoid injected into joints or muscle, is used for several inflammatory joint conditions.

• Osteoarthritis: reduces synovial inflammation and joint pain, improving function.
• Rheumatoid arthritis: diminishes synovial membrane swelling and systemic inflammatory activity.
• Bursitis: alleviates bursae inflammation, decreasing pain and restoring range of motion.
• Tendinitis: suppresses tendon sheath inflammation, facilitating recovery of tendon function.

• Triamcinolone acetonide binds to intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. This interaction up‑regulates anti‑inflammatory proteins such as annexin‑1 and down‑regulates pro‑inflammatory cytokines, chemokines and adhesion molecules, leading to reduced leukocyte migration, vascular permeability and fibroblast proliferation at the injection site. It also inhibits phospholipase A2 activity, decreasing prostaglandin and leukotriene synthesis.

Triamcinolone acetonide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects

• Pain at injection site: mild discomfort that usually resolves within a few days.
• Transient hyperglycemia: temporary rise in blood glucose, especially in diabetic patients.
• Mild flushing: brief redness of the skin near the injection area.
• Headache: occasional mild to moderate headache following administration.

Serious or Rare Side Effects

• Severe infection at injection site: cellulitis or abscess requiring medical attention.
• Adrenal suppression: reduced endogenous cortisol production with prolonged use.
• Allergic reaction including anaphylaxis: rash, swelling, breathing difficulty.
• Local tissue atrophy or necrosis: loss of subcutaneous tissue at the injection site.

When using Kenacort‑T, several precautionary measures should be observed to minimize risks.

• Assess blood glucose: monitor diabetic patients for hyperglycemia after injection.
• Monitor for infection: watch for signs of local or systemic infection at the injection site.
• Evaluate adrenal function: consider risk of adrenal suppression with repeated dosing.
• Use lowest effective dose: limit exposure by selecting the minimal dose needed for therapeutic effect.
• Avoid in patients with known hypersensitivity: contraindicated in individuals with allergy to triamcinolone or formulation components.
• Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Kenacort‑T can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Systemic corticosteroids: additive immunosuppression and adrenal suppression.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increased triamcinolone levels and toxicity.
• Live vaccines: reduced vaccine efficacy and increased infection risk.

Moderate Interactions (Monitor Closely)

• NSAIDs: heightened risk of gastrointestinal irritation or ulceration.
• Anticoagulants (e.g., warfarin): possible increase in bleeding tendency.